Ding Shun, Duan Tingting, Xu Zhengyang, Qiu Dongqin, Yan Jingren, Mu Zhonglin
Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital, Hainan Medical University, Haikou 570102, China.
Evid Based Complement Alternat Med. 2022 Feb 3;2022:4473231. doi: 10.1155/2022/4473231. eCollection 2022.
Chronic rhinosinusitis (CRS) is a complex condition brought on for many reasons, and its prevalence is rising gradually around the world. Xanthii Fructus (XF) has been used in the treatment of CRS for decades and is effective. The chemical and pharmacological profiles of XF, on the other hand, are still unknown and need to be clarified. The potential mechanisms of XF in CRS treatment were investigated using a network pharmacology approach in this study. OB and DL were in charge of screening the bioactive components in XF and drug-likeness. TCMSP and PubChem databases were used to identify prospective XF proteins, whereas GeneCards and the DisGeNET database were used to identify potential CRS genes. An interactive network of XF and CRS is built using the STRING database based on common goals identified by the online tool Venny. Cytoscape was used to visualize the topological characteristics of nodes, while the biological function pathways were identified by GO Knowledge Base, KEGG. There were 26 bioactive components and 115 potential targets in XF that bind to CRS or are considered therapeutically relevant. Five significant signaling pathways have been found for CRS by the pathway analysis including the HIF-1 signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, and PI3K-Akt signaling pathway. We simultaneously confirmed that the PI3K-Akt pathway promotes the development of CRS. Finally, this study took a holistic approach to the pharmacological actions and molecular mechanisms of XF in the treatment of CRS. TNF, INS, CCL2, CXCL8, IL-10, VEGFA, and IL-6 have all been identified as potential targets for anti-inflammatory and immune-boosting effects. This network pharmacology prediction could be useful in manifesting the molecular mechanisms of the Chinese herbal compound XF for CRS.
慢性鼻-鼻窦炎（CRS）是一种由多种原因引起的复杂病症，其在全球的患病率正在逐渐上升。辛夷已用于治疗CRS数十年且疗效显著。然而，辛夷的化学和药理特性仍不清楚，需要加以阐明。本研究采用网络药理学方法探讨辛夷治疗CRS的潜在机制。OB和DL负责筛选辛夷中的生物活性成分和类药性。利用中药系统药理学数据库与分析平台（TCMSP）和美国国立医学图书馆的化学物质数据库（PubChem）来识别潜在的辛夷蛋白，而利用基因卡片（GeneCards）和疾病基因数据库（DisGeNET）来识别潜在的CRS基因。基于在线工具Venny确定的共同靶点，使用STRING数据库构建辛夷与CRS的交互网络。利用Cytoscape可视化节点的拓扑特征，同时通过基因本体知识库（GO）、京都基因与基因组百科全书（KEGG）确定生物学功能通路。辛夷中有26种生物活性成分和115个潜在靶点与CRS相关或被认为具有治疗相关性。通过通路分析发现CRS有五条重要信号通路，包括缺氧诱导因子-1（HIF-1）信号通路、肿瘤坏死因子（TNF）信号通路、Toll样受体信号通路、NOD样受体信号通路和磷脂酰肌醇-3激酶-蛋白激酶B（PI3K-Akt）信号通路。我们同时证实PI3K-Akt通路促进CRS的发展。最后，本研究全面探讨了辛夷治疗CRS的药理作用和分子机制。肿瘤坏死因子（TNF）、胰岛素（INS）、趋化因子CCL2、趋化因子CXCL-8、白细胞介素-10（IL-10）、血管内皮生长因子A（VEGFA）和白细胞介素-6（IL-6）均已被确定为抗炎和增强免疫作用的潜在靶点。这种网络药理学预测可能有助于阐明中药复方辛夷治疗CRS的分子机制。
